Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Guillemin

Showing results (31-40 of 292) with videos related to

Pageof 30
Sort By:
Comptes Rendus Hebdomadaires Des Seances De L'Academie Des Sciences. Serie D: Sciences Naturelles|May 26, 1975
[The historic role of insulin in the physiopathology of the metabolic complications from pancreatic diabetes. Therapeutic implications for somatostatin]R Guillemin, M Fontaine
Endocrinology|March 1, 1986
hpGRF-44-NH2, lot no. 92-81-5G-41-47, is (human) growth hormone-releasing factor containing no trace of (ovine) corticotropin-releasing factorN Ling, R Guillemin
Annual Review of Biochemistry|January 1, 1970
Hypothalamic releasing factorsR Burgus, R Guillemin
Scientific American|November 1, 1972
The hormones of the hypothalamusR Guillemin, R Burgus
Diabetes|September 1, 1974
Growth hormone and diabetes in man. Old concepts--new implicationsR Luft, R Guillemin
Advances in Internal Medicine|January 1, 1972
Clinical applications of hypothalamic-releasing factorsN Fleischer, R Guillemin
Comptes Rendus Des Seances De L'Academie Des Sciences. Serie D, Sciences Naturelles|November 19, 1979
[Gonadostatin and gonadocrinin, polypeptides of ovarian origin with hypophysiotropic activity]S Y Ying, R Guillemin
The American Journal of Medicine|October 1, 1974
The hormones of the hypothalamusR E Peterson, R Guillemin
Nature|August 16, 1979
DTrp6-Pro9-NEt)-luteinising hormone-releasing factor inhibits follicular development in hypophysectomised ratsS Y Ying, R Guillemin
Annual Review of Medicine|January 1, 1976
Somatostatin: physiological and clinical significanceR Guillemin, J E Gerich
Pageof 30

Showing results (31-40 of 292) with videos related to

Sort By:
Pageof 30
Comptes Rendus Hebdomadaires Des Seances De L'Academie Des Sciences. Serie D: Sciences Naturelles|May 26, 1975
[The historic role of insulin in the physiopathology of the metabolic complications from pancreatic diabetes. Therapeutic implications for somatostatin]R Guillemin, M Fontaine
Endocrinology|March 1, 1986
hpGRF-44-NH2, lot no. 92-81-5G-41-47, is (human) growth hormone-releasing factor containing no trace of (ovine) corticotropin-releasing factorN Ling, R Guillemin
Annual Review of Biochemistry|January 1, 1970
Hypothalamic releasing factorsR Burgus, R Guillemin
Scientific American|November 1, 1972
The hormones of the hypothalamusR Guillemin, R Burgus
Diabetes|September 1, 1974
Growth hormone and diabetes in man. Old concepts--new implicationsR Luft, R Guillemin
Advances in Internal Medicine|January 1, 1972
Clinical applications of hypothalamic-releasing factorsN Fleischer, R Guillemin
Comptes Rendus Des Seances De L'Academie Des Sciences. Serie D, Sciences Naturelles|November 19, 1979
[Gonadostatin and gonadocrinin, polypeptides of ovarian origin with hypophysiotropic activity]S Y Ying, R Guillemin
The American Journal of Medicine|October 1, 1974
The hormones of the hypothalamusR E Peterson, R Guillemin
Nature|August 16, 1979
DTrp6-Pro9-NEt)-luteinising hormone-releasing factor inhibits follicular development in hypophysectomised ratsS Y Ying, R Guillemin
Annual Review of Medicine|January 1, 1976
Somatostatin: physiological and clinical significanceR Guillemin, J E Gerich
Pageof 30